Neurocrine Biosciences
NBIX
#1366
Rank
โ‚น1.393 T
Marketcap
โ‚น13,980
Share price
0.84%
Change (1 day)
30.58%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : โ‚น113.45 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are โ‚น113.45 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Neurocrine Biosciences - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚น96.85 B14.13%
2023-12-31โ‚น84.86 B55.17%
2022-12-31โ‚น54.68 B5.19%
2021-12-31โ‚น51.99 B16.83%
2020-12-31โ‚น44.50 B-6.73%
2019-12-31โ‚น47.71 B33.18%
2018-12-31โ‚น35.82 B25.96%
2017-12-31โ‚น28.44 B733.62%
2016-12-31โ‚น3.41 B2.01%
2015-12-31โ‚น3.34 B53.71%
2014-12-31โ‚น2.17 B2.79%
2013-12-31โ‚น2.11 B-7.07%
2012-12-31โ‚น2.27 B-44.99%
2011-12-31โ‚น4.14 B-26.11%
2010-12-31โ‚น5.60 B80.65%
2009-12-31โ‚น3.10 B-20.71%
2008-12-31โ‚น3.91 B-36.88%
2007-12-31โ‚น6.19 B86.72%
2006-12-31โ‚น3.32 B-20.68%
2005-12-31โ‚น4.18 B-22.92%
2004-12-31โ‚น5.43 B-27.2%
2003-12-31โ‚น7.45 B267.87%
2002-12-31โ‚น2.02 B16.87%
2001-12-31โ‚น1.73 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Repligen
RGEN
โ‚น75.56 B-33.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
โ‚น874.36 B 670.65%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
โ‚น0.90 B-99.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
โ‚น8.188 T 7,116.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
โ‚น12.270 T 10,715.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น10.395 T 9,062.11%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
โ‚น81.11 B-28.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
โ‚น3.93 B-96.53%๐Ÿ‡บ๐Ÿ‡ธ USA